First US Retail Trial with Target

RNS Number : 3364O

Byotrol PLC

17 May 2018

 

17^th May, 2018

Byotrol plc

("Byotrol" or the "Company") 

FURTHER PROGRESS IN THE US

MASS MARKET RETAIL TRIAL WITH TARGET

Byotrol plc, the specialist anti-microbial technology company, is pleased to announce that it has secured its first mass market retail trial in the US, for its 24-hour germ-kill surface sanitizer 'Byotrol24'.

The trial is due to take place over approximately 10-12 weeks at the national retailer Target. We are expecting the trial to start next month in approximately 10% of Target's 1,829 stores, following which Target will decide whether it wishes to roll-out into nationwide distribution.

This progress follows on closely from the Company having completed individual US State product registration earlier this month.  Byotrol24 received formal approval from the US Environmental Protection Agency in June 2017.

David Traynor, Chief Executive of Byotrol plc comments:

"This is really good news for Byotrol.  Target Corporation is one of the leading general merchandise retailers in the US and is well-known for innovation and design; it is a perfect retail match for our brand and an excellent first step in pursuing our US commercialisation ambitions."

Enquiries:

David Traynor - Chief Executive, Byotrol plc                                                                        01925 742 000

David Paton - Investor Relations                                                                                          07714 190 474

finnCap Ltd                                                                                                                           020 7220 0500 (Nominated Adviser & Broker)

Geoff Nash/Kate Bannatyne - Corporate Finance

Richard Chambers - Corporate Broking

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

Notes to Editors:

Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of residual antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.

Our patented suite of technologies deliver powerful broad-spectrum efficacy with residual performance optimised against commonly occurring and industry-specific pathogens.

Founded in 2005, the Company has developed advanced antimicrobial technologies that create easier, safer and cleaner lives for everyone.

For more information, please go to www.byotrol.co.uk

 

END

 

 

CNTLLFIRELIRLIT